Phase 3 Clinical Trials With Primary Completion Dates in October 2015
This is a list of Phase 3 trials with primary completion dates in October 2015 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ANTH | Anthera Pharmaceuticals, Inc. | 2015-10-01 | Phase 3 | NCT01395745 | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus |
| CHRS | Coherus BioSciences, Inc. | 2015-10-01 | Phase 3 | NCT02115750 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) |
| CYCC | Cyclacel Pharmaceuticals, Inc. | 2015-10-01 | Phase 3 | NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia |
| ONTX | Onconova Therapeutics, Inc. | 2015-10-01 | Phase 3 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |
| RIGL | Rigel Pharmaceuticals, Inc. | 2015-10-01 | Phase 3 | NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| RIGL | Rigel Pharmaceuticals, Inc. | 2015-10-01 | Phase 3 | NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |